Eli Lilly May Drop Inhaled Insulin Plan
Posted on: Saturday, 8 March 2008, 12:00 CST
Eli Lilly and Co. has pulled the plug on a collaboration with a Massachusetts company to develop inhaled insulin for diabetics.
Alkermes Inc. said it received a letter Friday from Lilly terminating the development and license agreement for AIR Inhaled Insulin. The announcement was made shortly after Alkermes released a statement that Lilly was evaluating its business case for the drug.
AIR Insulin is being evaluated in a broad phase-3 clinical trial program with patients with type 1 and type 2 diabetes. Alkermes said it was not aware of any safety, efficacy or manufacturing issues that would lead to the termination of the agreement.
Source: United Press International
Related Articles
- Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
- Lilly Announces Termination of AIR Insulin Program
- Alkermes Provides Update on Inhaled Insulin Program
- Alkermes Announces Initiation of Phase I Clinical Study of AIR(R) Parathyroid Hormone
- Alkermes and Lilly to Collaborate on Inhaled Osteoporosis Drug
- Alkermes and Lilly Announce Agreement for the Development and Commercialization of Inhaled Parathyroid Hormone for the Treatment of Osteoporosis
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin; 80 Percent of Diabetes Patients in Study Preferred Inhaled Insulin System to Mealtime Injections
- Eli Lilly Has Some Diabetics Scrambling
- Eli Lilly Will End Its Sale of 4 Insulins
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin
Rating: 2.3 / 5 (4 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds